Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 48,510 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Parkinson Disease
Interventions: [18F]MPPF; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 18 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Coronary Artery Disease, Angina Pectoris, Cardiac Valve Disease
Interventions: SternaLock Blue closure system, Suture Wire; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Jacksonville, Florida • Orlando, Florida • Atlanta, Georgia + 8 more

Conditions: Macular Edema, Branch Retinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more

Conditions: Type 2 Diabetes
Interventions: Targeted Self-Monitoring Of Blood Glucose (SMBG), Provider Training, Patient Education; Other
Lead sponsor: Biomedical Research Institute of New Mexico; Other
Eligibility: 18 Years to 85 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Phoenix, Arizona • Tucson, Arizona • Albuquerque, New Mexico

Conditions: Colorectal Carcinoma, Lynch Syndrome
Interventions: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Duarte, California • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Gut Health, Body Composition, Hair Growth, Skin Appearance, Healthy Weight Management, Gastrointestinal Health
Interventions: Cowboy Colostrum; Dietary Supplement
Lead sponsor: Cowboy Colostrum; Industry
Eligibility: 21 Years to 47 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Degenerative Disc Disease
Interventions: Rexlemestrocel-L + HA mixture, Saline; Drug
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 37 more

Conditions: Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)
Interventions: Bright Light Therapy; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Rosacea
Interventions: B244, Vehicle; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Clearwater, Florida • Miami, Florida • Miramar, Florida + 4 more

Conditions: Chronic Pain, Pain
Interventions: Mindfulness-Based Stress Reduction, Cognitive Behavioral Therapy for Chronic Pain, Usual Care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Solid Tumor
Interventions: Selinexor, Acetaminophen; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Tampa, Florida • Detroit, Michigan • New York, New York + 1 more

Conditions: Metastatic Cancer
Interventions: temozolomide, vinorelbine tartrate; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions: E7050, Cetuximab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 7
States / cities: Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 4 more

Conditions: Asthma
Interventions: Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more

Conditions: Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer
Interventions: ART0380; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Forgiveness
Interventions: Forgiveness Therapy, Carey Guides; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portage, Wisconsin

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 64
States / cities: Concord, California • Fresno, California • Fullerton, California + 56 more

Conditions: Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
Interventions: Bariatric surgery; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Child Abuse, Child Neglect, Risk Behavior, Delinquency, Mental Health Impairment, Substance Use, Educational Problems, Adolescent Development, Adolescent Behavior, Sexual Behavior, Child Maltreatment
Interventions: FHF-T; Behavioral
Lead sponsor: University of Denver; Other
Eligibility: 13 Years to 16 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2044
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC)
Interventions: MK-3475, INCB024360; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 19 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Brain and Central Nervous System Tumors
Interventions: filgrastim, cisplatin, cyclophosphamide, vincristine, autologous hematopoietic stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 3 Years to 21 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2023
U.S. locations: 4
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more

Conditions: Choanal Atresia
Interventions: Drug-eluting Stent Mometasone; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Glioblastoma
Interventions: Treatment with hP1A8; Drug
Lead sponsor: OX2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a

An Evaluation of Rigid Sternal Fixation in Supporting Bone Healing and Improving Postoperative Recovery

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

A Clinical Trial to Evaluate the Effects of Cowboy Colostrum on Gut Health, Body Composition, Hair Growth, and Skin Appearance

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

An Evaluation of MBSR and CBT for Veterans With Chronic Pain

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

Study of ART0380 in Patients With Biologically Selected Solid Tumors

Proposing Forgiveness Therapy Within Prison

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

Fostering Healthy Futures for Teens: An RCT

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Use of Mometasone Eluting Stent in Choanal Atresia

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma